The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Opportunistic pulmonary/systemic infections
Publications
Laryngeal aspergilloma: a complication of inhaled fluticasone therapy for asthma.
Respirology case reports 2014 Dec;2;123-5 — 2014 Dec — 123-5
[Risk of pneumonia with inhaled corticosteroids for stable chronic obstructive pulmonary disease patients].
Medicina clinica 2011 Sep 17;137;302-4 — 2011 Sep 17 — 302-4
Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
The European respiratory journal 2009 Sep;34;641-7 — 2009 Sep — 641-7
Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis.
JAMA 2008 Nov 26;300;2407-16 — 2008 Nov 26 — 2407-16
Invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002 Sep 01;35;e54-6 — 2002 Sep 01 — e54-6
Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone.
The New England journal of medicine 2000 Aug 24;343;586 — 2000 Aug 24 — 586